Drug
Gamma-Glutamyl Hydrolase clinical trials
- studies test it
- 3
- open now
- 0
- in phase 3
- 0
- first study started
- 1992
How studies write it
Studies that test it under each name
Combined with it in one product
Studies by the year they started
3 studies that test it; most in 2021 (2)
| Year | Studies |
|---|---|
| 1992 | 1 |
| 2021 | 2 |
By phase
A phase 1/2 study counts in both.
What it is tested for
Each study’s main condition, where its own words name it.
Who runs them
Industry 0 · Other 3
Charite University, Berlin, Germany (1) · National Cancer Institute (NCI) (1) · Fundacion CRIS de Investigación para Vencer el Cáncer (1)
Often tested with
Tested in the same studies.
Studies
Open first, then newest update. How each study uses gamma-Glutamyl Hydrolase is read from its arms, and is right about nine times in ten.
Testing it · 3
- A Phase I/II Study to Investigate the Use of VORAXAZE™ As Intended Intervention in Patients with CNSLCompletedPhase 1/2Charite University, Berlin, GermanyNCT04841434Written as Voraxaze Injectable Product
- Reduction of MTX Levels After Glucarpidase Treatment in DLBCL Patients at Risk of CNSTerminatedPhase 2Fundacion CRIS de Investigación para Vencer el CáncerNCT05022797Written as Glucarpidase 1000 UNT [Voraxaze]
- A Trial of Carboxypeptidase-G2 (CPDG2) and Thymidine for the Management of Patients With Methotrexate Toxicity and Renal DysfunctionCompletedPhase 1National Cancer Institute (NCI)NCT00001298Written as carboxypeptidase-G2
Codes
What other systems call gamma-Glutamyl Hydrolase · ClinicalTrials.gg INT008128
- RxNorm 1242127One source FDA
| System | Code | Name there | Checked by |
|---|---|---|---|
| RxNorm | 1242127 | — | One source FDA |
“Confirmed” means two independent publishers link the code to this drug; “one source”, one does and its name agrees.